News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Amgen Drug AMG-102 Has Little Impact On Brain Cancer
May 16, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LOS ANGELES, May 15 (Reuters) - Amgen Inc's (AMGN.O: Quote, Profile, Research) experimental drug AMG-102 may be effective in only a subpopulation of patients with recurring brain tumors, according to results from a small mid-stage trial.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
MORE ON THIS TOPIC
Obesity
Metsera’s Obesity Drug Shows ‘Very Encouraging’ Mid-Stage Efficacy, Supporting Pfizer’s $4.9B Bet
September 30, 2025
·
2 min read
·
Tristan Manalac
Friedreich’s ataxia
Larimar’s Friedreich’s Ataxia Drug Troubled by Anaphylaxis Concerns; Shares Fall
September 30, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
New Confirmatory Study Hints at ‘Alignment’ Between Applied Therapeutics, FDA for Rare Disease Drug
September 29, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Hansa Kidney Transplant Drug Aces Phase III Study, Headed to FDA
September 26, 2025
·
2 min read
·
Tristan Manalac
